Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study
Authors:
- 1 November 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 47 (10) , e91-e95
Abstract
Goals: To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study. Background: In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study, the participation of 76 academic-based and 42 community-based US centers provided an opportunity to evaluate various metrics of quality and site performance. Study: A secondary data analysis of the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study was performed. There were 3070 treatment-naive, hepatitis C virus genotype 1 infected patients were included. We retrospectively evaluated rates of screen failure, completion, and discontinuation of treatment and follow-up, treatment adherence, and virologic response by site type. Results: Of the patients screened, 63% and 37% were in academic and community centers, respectively. Screen failure rates were similar (30% to 32%). End-of-treatment response, relapse, and sustained virologic response (SVR) rates in academic and community centers did not differ. SVR was achieved in 40% of patients at academic sites and 39% at community sites. Adherence to ≥80% of peginterferon-α and ribavirin dosing for ≥80% assigned duration was also similar (46% in academic and 47% in community centers). In both academic and community centers, 54% of patients completed treatment; there were similar discontinuation rates for treatment failure and adverse events. Conclusions: There were no significant differences in adherence, adverse events, rates of discontinuation, on-treatment virologic response, and SVR when comparing academic and community sites. The performance of academic-based and experienced community-based sites in clinical trials is largely similar for the treatment of chronic hepatitis C.Keywords
This publication has 7 references indexed in Scilit:
- Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a and Ribavirin at Academic and Community Centres in Canada)Canadian Journal of Gastroenterology and Hepatology, 2011
- Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment SettingJournal of Clinical Oncology, 2010
- Efficacy of Chronic Hepatitis C Therapy in Community-Based TrialsClinical Gastroenterology and Hepatology, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patientsHepatology, 2007
- A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centresAlimentary Pharmacology & Therapeutics, 2003
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001